Apollomics vs Coya Therapeutics
Apollomics and Coya Therapeutics are similar in size: $8.5m and $7.9m of revenue in their latest fiscal years. Apollomics kept more of each dollar of sales as profit: a net margin of -128.7% against -267.1%.
| Latest fiscal year | ApollomicsAPLM, 2025 | Coya TherapeuticsCOYA, 2025 |
|---|---|---|
| Revenue | $8.5m | $7.9m |
| Revenue growth | — | 123.6% |
| Net income | −$10.9m | −$21.2m |
| Operating margin | — | -283.9% |
| Net margin | -128.7% | -267.1% |
| Return on equity | — | -51.4% |
| Free cash flow | −$10.4m | — |
| Cash | $3.3m | $46.8m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $30.1m | $73.5m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 0 sales | 0 buys, 0 sales |